Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADORE-BARI Study: Baricitinib Plus Corticosteroids in Polymyalgia Rheumatica
NCT07279688Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Dec 2025
- Primary completion
- Nov 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in polymyalgia rheumatica (PMR), sponsored by Centre Hospitalier Universitaire de Brest. Started Dec 2025; status: recruiting.
02
Drugs
baricitinib
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT07279688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279688.